Mode
Text Size
Log in / Sign up

Gut-derived metabolites and microbiota may influence ocular-surface homeostasis in Type 2 Diabetes and Dry EyeGut Health and Short Chain Fatty Acids May Impact Dry Eyes

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that gut-derived metabolites may influence ocular-surface health in T2DM, but human evidence is currently lacking.

This narrative review synthesizes current evidence regarding the impact of the intestinal microbiota and gut-derived metabolites, specifically short-chain fatty acids (SCFAs), on ocular-surface homeostasis in patients with Type 2 Diabetes (T2DM) and Dry Eye Disease (DED). The review highlights that human studies in T2DM consistently report complications such as neuropathy, corneal sensory or nerve changes, meibomian dysfunction, and lacrimal injury.

Experimental models and disease-matched animal studies provide the primary evidence for the gut-microbiota link. These studies suggest that probiotic-prebiotic interventions can influence intestinal, lacrimal, inflammatory, and dry-eye-like features. Furthermore, experimental models support macrophage-dependent corneal nerve repair and SCFA-responsive ocular-surface homeostasis. However, the authors note that these findings establish model-specific effects rather than a continuous human pathway.

Significant limitations include the absence of human studies that jointly measure intestinal microbiota or gut-derived metabolites alongside T2DM-DED outcomes. The necessity, sufficiency, and mediation of SCFAs in T2DM-DED remain unknown. While oral Chinese herbal medicine is mentioned as a standardizable perturbation for testing, it is not currently an established gut-mediated therapy. Clinical application is limited by the current lack of direct human evidence linking gut-derived metabolites to T2DM-DED outcomes.

How this fits prior evidence

This narrative review addresses a gap in the management of Dry Eye Disease in patients with Type 2 Diabetes. While prior coverage has established the efficacy of non-pharmacological interventions, such as structured exercise and Taijiquan and Baduanjin, for managing metabolic outcomes and depressive symptoms in Type 2 Diabetes, this review explores a specific biological pathway involving the gut-microbiota axis and short-chain fatty acids to address ocular-surface complications.

Researchers are looking into the link between gut health and dry eye disease, especially in people with Type 2 Diabetes. This condition often involves issues like nerve changes in the eye, inflammation, and problems with the oil glands in the eyelids. The review looked at how the gut microbiome and certain substances called short-chain fatty acids might affect these symptoms.

While human studies show that people with Type 2 Diabetes often experience dry eye issues, there are currently no human studies that directly link gut health to these specific eye symptoms. However, animal studies did show that using probiotics and prebiotics led to improvements in dry-eye-like features and inflammation. These results suggest that the gut might influence how the eye responds to stress.

It is important to note that these findings are based on animal models and experimental studies rather than direct human clinical trials. Because of this, the exact role of gut-derived metabolites in human dry eye is not yet clear. These findings are early and do not currently offer a proven treatment for dry eyes.

What this means for you:
Early research suggests a link between gut health and dry eye symptoms in Type 2 Diabetes, but more human studies are needed.

Common questions

Can probiotics help with dry eyes in people with diabetes?

Animal studies showed that a probiotic and prebiotic combination led to changes in dry-eye-like features and inflammation. However, there are no human studies yet that directly link gut-derived metabolites to dry eye outcomes in people with Type 2 Diabetes.

What is the role of short-chain fatty acids in eye health?

Experimental models suggest that short-chain fatty acids may help maintain balance on the surface of the eye. However, their exact role and necessity in human patients with Type 2 Diabetes and dry eye disease are not yet known.

Is this a proven treatment for dry eye disease?

No, these findings are not a proven treatment. The current evidence comes from animal models and experimental studies rather than human trials, so the results do not yet establish a clear path for human medical treatment.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedNov 2026
View Original Abstract ↓
Type 2 diabetes mellitus (T2DM)-associated dry eye disease (DED) includes aqueous, evaporative, epithelial, inflammatory, and neurosensory phenotypes. Intestinal dysbiosis may contribute to some of these abnormalities, but the clinical and mechanistic evidence has not yet been synthesised in terms of disease relevance and causal strength. We conducted a structured narrative review using iterative PubMed searches, full-text retrieval from PubMed Central and publisher websites, and backward citation tracing. The evidence pool was updated to 26 July 2026. Human studies in T2DM consistently report neuropathy, corneal sensory or nerve changes, meibomian dysfunction, and lacrimal injury, but no human study jointly measuring intestinal microbiota or gut-derived metabolites with T2DM-DED outcomes was found. One disease-matched animal study linked a probiotic–prebiotic intervention with changes in intestinal, lacrimal, inflammatory, and dry-eye-like features. Other experimental models support microbiota-sensitive lacrimal responses, macrophage-dependent corneal nerve repair, and short-chain fatty acid (SCFA)-responsive ocular-surface homeostasis. Taken together, these findings establish model-specific effects rather than a continuous human pathway. SCFAs are therefore considered a hypothesis-prioritised candidate based on cross-model breadth, although their necessity, sufficiency, and mediation in T2DM-DED remain unknown. Diet, glycaemic control, obesity, renal function, neuropathy, medicines, and ocular treatment are important clinical confounders. Future studies should combine longitudinal human co-phenotyping with a disease-matched mediation experiment that measures intestinal, metabolic, lacrimal, corneal-neural, and ocular-surface outcomes in the same temporal sequence. Oral Chinese herbal medicine is presented only as one standardisable perturbation for such testing, rather than as an established gut-mediated therapy.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.